Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 36 | 2020 | 88 | 3.590 |
Why?
|
| Choroid Neoplasms | 16 | 2020 | 20 | 3.080 |
Why?
|
| Fluorescein Angiography | 29 | 2022 | 57 | 2.990 |
Why?
|
| Retinal Neoplasms | 16 | 2019 | 22 | 2.410 |
Why?
|
| Melanoma | 17 | 2020 | 335 | 2.370 |
Why?
|
| Retinal Diseases | 9 | 2020 | 40 | 2.280 |
Why?
|
| Retinoblastoma | 14 | 2019 | 26 | 1.880 |
Why?
|
| Retina | 8 | 2021 | 252 | 1.850 |
Why?
|
| Uveal Neoplasms | 9 | 2018 | 16 | 1.600 |
Why?
|
| Brachytherapy | 10 | 2020 | 79 | 1.480 |
Why?
|
| Choroid Diseases | 5 | 2017 | 6 | 1.460 |
Why?
|
| Visual Acuity | 19 | 2020 | 236 | 1.360 |
Why?
|
| Fovea Centralis | 6 | 2019 | 11 | 1.280 |
Why?
|
| Retinal Vessels | 8 | 2019 | 74 | 1.090 |
Why?
|
| Retinal Pigment Epithelium | 5 | 2022 | 145 | 1.070 |
Why?
|
| Macular Degeneration | 2 | 2017 | 75 | 0.950 |
Why?
|
| Radiation Injuries | 4 | 2020 | 97 | 0.930 |
Why?
|
| West Nile virus | 1 | 2022 | 8 | 0.850 |
Why?
|
| Retinal Detachment | 6 | 2020 | 14 | 0.810 |
Why?
|
| Fundus Oculi | 13 | 2021 | 33 | 0.760 |
Why?
|
| Choroid | 5 | 2018 | 22 | 0.750 |
Why?
|
| Aminopyridines | 1 | 2020 | 26 | 0.730 |
Why?
|
| Capillaries | 6 | 2020 | 105 | 0.720 |
Why?
|
| Pyrroles | 1 | 2020 | 83 | 0.700 |
Why?
|
| Conjunctival Neoplasms | 3 | 2017 | 3 | 0.690 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 175 | 0.680 |
Why?
|
| Ciliary Arteries | 2 | 2017 | 2 | 0.640 |
Why?
|
| Retinal Artery | 2 | 2017 | 10 | 0.640 |
Why?
|
| Vitrectomy | 2 | 2020 | 21 | 0.630 |
Why?
|
| Optical Imaging | 1 | 2017 | 46 | 0.580 |
Why?
|
| Middle Aged | 33 | 2020 | 21147 | 0.580 |
Why?
|
| Female | 51 | 2021 | 38074 | 0.560 |
Why?
|
| Humans | 70 | 2022 | 68618 | 0.550 |
Why?
|
| Eye Neoplasms | 4 | 2017 | 10 | 0.550 |
Why?
|
| Retrospective Studies | 30 | 2022 | 7277 | 0.530 |
Why?
|
| Orbital Neoplasms | 2 | 2012 | 21 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2016 | 468 | 0.490 |
Why?
|
| Male | 45 | 2020 | 37321 | 0.470 |
Why?
|
| Aged | 25 | 2020 | 14862 | 0.460 |
Why?
|
| Hamartoma | 4 | 2019 | 24 | 0.460 |
Why?
|
| Automation | 1 | 2013 | 45 | 0.430 |
Why?
|
| Infant | 18 | 2021 | 2891 | 0.430 |
Why?
|
| Aged, 80 and over | 13 | 2019 | 4848 | 0.430 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2012 | 4 | 0.410 |
Why?
|
| Conjunctival Diseases | 1 | 2011 | 2 | 0.390 |
Why?
|
| Hemangioma | 3 | 2018 | 51 | 0.390 |
Why?
|
| Amlodipine | 1 | 2011 | 31 | 0.380 |
Why?
|
| Stem Cells | 1 | 2013 | 248 | 0.380 |
Why?
|
| Triamcinolone Acetonide | 1 | 2011 | 10 | 0.380 |
Why?
|
| Hypopigmentation | 1 | 2011 | 12 | 0.380 |
Why?
|
| Skin Pigmentation | 1 | 2011 | 25 | 0.380 |
Why?
|
| Child | 19 | 2020 | 6405 | 0.370 |
Why?
|
| Glucocorticoids | 2 | 2015 | 222 | 0.360 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 1070 | 0.360 |
Why?
|
| Melphalan | 5 | 2016 | 15 | 0.340 |
Why?
|
| Nerve Fibers | 3 | 2020 | 77 | 0.340 |
Why?
|
| Adipose Tissue | 1 | 2011 | 221 | 0.340 |
Why?
|
| Adult | 28 | 2020 | 21403 | 0.340 |
Why?
|
| Retinal Ganglion Cells | 3 | 2020 | 72 | 0.330 |
Why?
|
| Adolescent | 20 | 2020 | 8912 | 0.330 |
Why?
|
| Macula Lutea | 3 | 2019 | 6 | 0.330 |
Why?
|
| Optic Nerve Diseases | 2 | 2020 | 31 | 0.320 |
Why?
|
| Macular Edema | 3 | 2018 | 21 | 0.310 |
Why?
|
| Neoplasm Seeding | 3 | 2016 | 7 | 0.300 |
Why?
|
| Hemangioblastoma | 2 | 2018 | 6 | 0.290 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 498 | 0.290 |
Why?
|
| Chromosome Aberrations | 2 | 2017 | 86 | 0.280 |
Why?
|
| Child, Preschool | 13 | 2020 | 3187 | 0.280 |
Why?
|
| Eye Diseases | 2 | 2016 | 38 | 0.260 |
Why?
|
| Vitreous Body | 2 | 2016 | 26 | 0.260 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 800 | 0.250 |
Why?
|
| Ciliary Body | 2 | 2017 | 52 | 0.250 |
Why?
|
| Fluorescence | 2 | 2017 | 104 | 0.250 |
Why?
|
| Iris Neoplasms | 2 | 2017 | 5 | 0.250 |
Why?
|
| Young Adult | 12 | 2019 | 5717 | 0.240 |
Why?
|
| Topotecan | 4 | 2016 | 17 | 0.240 |
Why?
|
| Diagnosis, Differential | 9 | 2018 | 1140 | 0.230 |
Why?
|
| Nevus, Pigmented | 2 | 2016 | 30 | 0.230 |
Why?
|
| Intravitreal Injections | 5 | 2016 | 16 | 0.220 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 306 | 0.220 |
Why?
|
| Radiotherapy Dosage | 3 | 2020 | 125 | 0.210 |
Why?
|
| Retinal Dystrophies | 1 | 2022 | 4 | 0.210 |
Why?
|
| Retinitis Pigmentosa | 1 | 2022 | 17 | 0.210 |
Why?
|
| Multimodal Imaging | 1 | 2022 | 62 | 0.210 |
Why?
|
| Dyskeratosis Congenita | 1 | 2021 | 2 | 0.200 |
Why?
|
| Retinal Telangiectasis | 1 | 2021 | 2 | 0.200 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2021 | 30 | 0.200 |
Why?
|
| Nevus | 2 | 2018 | 17 | 0.190 |
Why?
|
| Vitreoretinal Surgery | 1 | 2020 | 1 | 0.190 |
Why?
|
| Bone Marrow | 1 | 2021 | 168 | 0.190 |
Why?
|
| Subretinal Fluid | 2 | 2018 | 3 | 0.180 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2018 | 7 | 0.180 |
Why?
|
| Optic Disk | 1 | 2020 | 37 | 0.180 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 95 | 0.180 |
Why?
|
| Pigment Epithelium of Eye | 2 | 2017 | 28 | 0.170 |
Why?
|
| Myelin Sheath | 1 | 2019 | 115 | 0.160 |
Why?
|
| Choroidal Neovascularization | 1 | 2018 | 35 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2017 | 16 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1173 | 0.150 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2017 | 79 | 0.150 |
Why?
|
| Ischemia | 1 | 2019 | 229 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 20 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2017 | 56 | 0.150 |
Why?
|
| Conjunctiva | 1 | 2017 | 16 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2017 | 3705 | 0.150 |
Why?
|
| Retinoschisis | 1 | 2017 | 2 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2017 | 54 | 0.140 |
Why?
|
| Endoscopy | 1 | 2020 | 464 | 0.140 |
Why?
|
| Optics and Photonics | 1 | 2017 | 29 | 0.140 |
Why?
|
| Meningocele | 1 | 2017 | 12 | 0.140 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 14 | 0.140 |
Why?
|
| Varicose Veins | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cataract Extraction | 1 | 2018 | 127 | 0.140 |
Why?
|
| Retinal Neovascularization | 1 | 2016 | 7 | 0.140 |
Why?
|
| Retinopathy of Prematurity | 2 | 2020 | 34 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1553 | 0.140 |
Why?
|
| Artifacts | 1 | 2017 | 125 | 0.140 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2016 | 10 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2017 | 249 | 0.140 |
Why?
|
| Cataract | 1 | 2018 | 134 | 0.140 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2016 | 7 | 0.140 |
Why?
|
| Abatacept | 1 | 2016 | 17 | 0.140 |
Why?
|
| Vacuoles | 1 | 2016 | 10 | 0.140 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 45 | 0.140 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2016 | 2 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2018 | 249 | 0.140 |
Why?
|
| Tetraspanins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Anterior Chamber | 1 | 2016 | 20 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 57 | 0.130 |
Why?
|
| Melanosis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2016 | 74 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 248 | 0.130 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2015 | 4 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2016 | 112 | 0.130 |
Why?
|
| Carboplatin | 4 | 2016 | 59 | 0.120 |
Why?
|
| Ultrasonography | 5 | 2017 | 453 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 186 | 0.120 |
Why?
|
| Cholesterol | 1 | 2016 | 331 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.120 |
Why?
|
| Astrocytes | 1 | 2016 | 270 | 0.110 |
Why?
|
| Dilatation, Pathologic | 1 | 2013 | 58 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 64 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2018 | 7029 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3259 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 151 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 132 | 0.110 |
Why?
|
| Ophthalmia, Sympathetic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 514 | 0.100 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2012 | 3 | 0.100 |
Why?
|
| Drug Resistance, Viral | 1 | 2012 | 14 | 0.100 |
Why?
|
| Healthy Volunteers | 3 | 2017 | 78 | 0.100 |
Why?
|
| Ganciclovir | 1 | 2012 | 27 | 0.100 |
Why?
|
| Osteoma | 1 | 2011 | 6 | 0.100 |
Why?
|
| Plasma | 1 | 2012 | 58 | 0.100 |
Why?
|
| Choristoma | 1 | 2011 | 20 | 0.100 |
Why?
|
| Lymphopenia | 1 | 2011 | 12 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 13 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2013 | 489 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 2011 | 33 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 375 | 0.100 |
Why?
|
| Cytomegalovirus | 1 | 2012 | 63 | 0.100 |
Why?
|
| Port-Wine Stain | 1 | 2011 | 7 | 0.100 |
Why?
|
| Iridocorneal Endothelial Syndrome | 1 | 2011 | 1 | 0.100 |
Why?
|
| Foot Diseases | 1 | 2011 | 20 | 0.100 |
Why?
|
| Fascia | 1 | 2011 | 17 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 47 | 0.090 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2016 | 27 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 20 | 0.090 |
Why?
|
| Edema | 1 | 2011 | 66 | 0.090 |
Why?
|
| Welding | 1 | 2010 | 2 | 0.090 |
Why?
|
| Atrophy | 1 | 2011 | 112 | 0.090 |
Why?
|
| Eye Enucleation | 3 | 2016 | 6 | 0.090 |
Why?
|
| Vincristine | 3 | 2016 | 44 | 0.090 |
Why?
|
| Iodine Radioisotopes | 3 | 2020 | 119 | 0.090 |
Why?
|
| Etoposide | 3 | 2016 | 64 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 201 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 235 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2010 | 68 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2010 | 79 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 226 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2012 | 211 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 384 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2020 | 2455 | 0.080 |
Why?
|
| Antigens, Neoplasm | 2 | 2022 | 132 | 0.070 |
Why?
|
| Ophthalmoscopy | 2 | 2017 | 13 | 0.070 |
Why?
|
| Eye Injuries | 2 | 2020 | 18 | 0.070 |
Why?
|
| Microscopy, Acoustic | 2 | 2017 | 4 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 76 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 536 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2011 | 1330 | 0.070 |
Why?
|
| Equipment Design | 2 | 2017 | 500 | 0.070 |
Why?
|
| Ophthalmic Artery | 2 | 2016 | 4 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 446 | 0.050 |
Why?
|
| Usher Syndromes | 1 | 2022 | 5 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2022 | 24 | 0.050 |
Why?
|
| Risk Factors | 3 | 2018 | 5731 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2022 | 81 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2022 | 108 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2022 | 120 | 0.050 |
Why?
|
| Hypertension | 1 | 2011 | 1535 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2077 | 0.050 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2020 | 2 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 230 | 0.050 |
Why?
|
| Glaucoma | 1 | 2020 | 50 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 191 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2022 | 370 | 0.040 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 2018 | 31 | 0.040 |
Why?
|
| Iris | 1 | 2017 | 27 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2017 | 30 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 277 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 12 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
| Retinal Vein | 1 | 2016 | 4 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2016 | 8 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 144 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 159 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 43 | 0.030 |
Why?
|
| Cell Count | 1 | 2017 | 248 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2016 | 19 | 0.030 |
Why?
|
| Persistent Hyperplastic Primary Vitreous | 1 | 2016 | 4 | 0.030 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2016 | 10 | 0.030 |
Why?
|
| Photography | 1 | 2016 | 37 | 0.030 |
Why?
|
| Video Recording | 1 | 2017 | 145 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 240 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 83 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2016 | 168 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 215 | 0.030 |
Why?
|
| South Carolina | 1 | 2022 | 2752 | 0.030 |
Why?
|
| Bone Density | 1 | 2016 | 159 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2015 | 143 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 737 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 705 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2015 | 122 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2013 | 34 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 540 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 424 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 951 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2013 | 94 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1603 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 219 | 0.030 |
Why?
|
| Foscarnet | 1 | 2012 | 3 | 0.030 |
Why?
|
| Cytosine | 1 | 2012 | 12 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2012 | 16 | 0.030 |
Why?
|
| Prednisone | 1 | 2012 | 104 | 0.030 |
Why?
|
| Methotrexate | 1 | 2012 | 91 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 2334 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2011 | 11 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2012 | 114 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 334 | 0.020 |
Why?
|
| Eye Color | 1 | 2011 | 1 | 0.020 |
Why?
|
| Eye | 1 | 2012 | 89 | 0.020 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2011 | 7 | 0.020 |
Why?
|
| Endothelium, Corneal | 1 | 2011 | 20 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 208 | 0.020 |
Why?
|
| Trabecular Meshwork | 1 | 2011 | 22 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 164 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 234 | 0.020 |
Why?
|
| Calcinosis | 1 | 2011 | 241 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2279 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2010 | 240 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 307 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 508 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 334 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1174 | 0.020 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.020 |
Why?
|